Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836549 · ClinicalTrials.gov registry record · Phase 2
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
A Phase 2 study, sponsored by Pediatric Brain Tumor Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01836549: Clinical Trial Phase 2 study, sponsored by Pediatric Brain Tumor Consortium.
NCT01836549 is a Phase 2 study that was terminated before completion, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01836549, a Phase 2 study, was terminated before completion, sponsored by Pediatric Brain Tumor Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
This outcome measure is for the Molecular biology study only. The assessment was done to identify cases with at least 50% reduction in telomerase activity.
Interventions
- DRUG imetelstat sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Why NCT01836549 stopped before completion
NCT01836549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which imetelstat sodium is the first listed.
NCT01836549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01836549 about?
NCT01836549 is a clinical study titled "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors". This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01836549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01836549?
The interventions under investigation include: imetelstat sodium (DRUG).
Who is sponsoring clinical trial NCT01836549?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01836549's enrollment target sits among peer trials
43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia